Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

PDS Biotechnology Corp

NASDAQ: PDSB · Life Sciences · 8 alerts · CIK 1472091

Share price
$0.9241Close, Nov 16
Market cap
$97M
Shares outstanding
105.01MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All PDS Biotechnology Corp filings on SEC EDGAR ↗

8:05 AM ET 8-K
Financial Results

PDS Biotechnology Financial Results

PDS Biotechnology reported third quarter 2026 financial results, highlighting a strategic shift to PDS0301 as its lead development program. The company also noted the initial closing of a $22.3 million PIPE financing led by Nant Capital and the appointment of several new board members, including Dr. Patrick Soon-Shiong.

“During our third quarter, we continued to execute our strategic prioritization of PDS0301, our investigational tumor-targeted IL-12 immunocytokine, as our lead development program. We believe the ongoing clinical trials of PDS0301 at the NCI, along with those of our cancer vaccine platform, support our view that targeted T cell immunotherapy has the potential to change how solid tumors are treated.”

Frank Bedu-Addo, PhD, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.